CymaBay price target raised to $23 from $21 at H.C. Wainwright. H.C. Wainwright analyst Ed Arce raised his price target for CymaBay Therapeutics to $23 saying the company is well positioned to successfully execute its strategy with seladelpar. The analyst reiterates a Buy rating on the shares
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.